Clinical Trials · NCT07684235
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Phase
- Phase 3
- Recruitment status
- Recruiting
- Sponsor
- Amgen
- Enrollment
- 3,200
- Start date
- Jul 2026
- Locations
- 83 sites, 4 countries
- Primary endpoint
- Percent Change in Body Weight from Baseline of the Parent Trial (20210181)